ISSN 2415-3060 (print), ISSN 2522-4972 (online)
  • 38 of 50
Up
JMBS 2016, 1(2): 172–175
https://doi.org/10.26693/jmbs01.02.172
Medicine

Anti-Stress Effect L-Tryptophan and its Metabolic Correlates, as a Predictor of Neurological Diseases

Savchenko V.N.1, Kratenko A.S.1, Nikolenko E.Ya.1, Sokruto O.V.1, Vovk K.V.1, Letik I.V.2, Kvitchataya A.I.3
Abstract

Stress is an important mechanism for the preservation and maintenance of homeostasis in living systems. At the same time, from 75 to 90% of all human diseases associated with activation of stress mechanisms.The search for effective stressoprotektor most relevant among the compounds that affect the physiological mechanisms of protection from stress. Of particular interest are the main means of action neurotransmitter amino acid tryptophan. The contents of these metabolites in the bore, wherein the body serotonergic neurons are changed as follows. The levels of tryptophan and kynurenine are reduced, serotonin is not changed. L-tryptophan normalizes the kynurenine, but not tryptophan, in the trunk. The level of serotonin in the structure is not changed in this structure, the introduction of L-tryptophan. Condition of tryptophan metabolism in the cerebellum in status epilepticus include tryptophan and serotonin levels are significantly reduced, and kynurenine is not changed. Exogenous L-tryptophan will not restore the level of the substrate, but normalizes increases serotonin and kynurenine in the cerebellum. L-tryptophan under ES affects the metabolism of tryptophan in various brain structures, which is manifested by reduction of the level of its metabolites. Introduction of these conditions causes the L-tryptophan restore serotonin levels in the cerebellum and hypothalamus, kynurenine - all structures except cortex, increasing it to above normal cerebellum. Stress-protective effect of L-tryptophan is probably due to increased synthesis of serotonin.

Keywords: stress, tryptophan

Full text: PDF (Rus) 81.11K

References
  1. Barabay VA. Stress: priroda, biologicheskaya rol, mehanizmyi, ishodyi. Kiev: Fitotsentr; 2006. 424 s.
  2. Bibleyshvili ShI. Aminokislota triptofan kak protivoepilepticheskoe sredstvo. Klin. meditsina. 1980; 58 (1): 91-6.
  3. Izzatizade KF, Basha AV, Demchuk N. Narushenie obmena serotonina v patogeneze zabolevaniy nervnoy sistemyi. Zhurnal nevrologii i psihiatrii im SS Korsakova. 2004; 9: 62-70.
  4. Kirichek LT, Dubenko EG, Perepelitsa AV, i dr. Perspektivyi klinicheskogo primeneniya stressprotektorov. Klinicheskaya farmakologiya. 2009; 2: 116-9.
  5. Kirichek LT. Stressprotektoryi v eksperimente i v klinike. Kh: «Kontrakt»; 2008. 302 s.
  6. Starovoytova EE. Primenenie triptofana dlya lecheniya zaderzhki psihicheskogo razvitiya pri nervno-psihicheskih zabolevaniyah. Patent RF № 2395279. 2008.
  7. Frolova GA, Fedotova YuO, Kuznetsov IE. Vliyanie selektivnogo stimulirovaniya aktivnosti monoaminergicheskih neyromediatornyih sistem mozga na psihoemotsionalnyiy status samtsov belyih kryis. Visnik problem biologiyi i meditsini. 2012; 2 (92): 101-6.
  8. Miller CL, Llenos IC, Dulay JR, Barillo MM, Yolken RH, Weis S. Expression of the kynurenine pathway enzyme tryptophan 2,3-dioxygenase is increased in the frontal cortex of individuals with schizophrenia. Neurobiol. Dis. 2004; 15 (3): 618–29. https://www.ncbi.nlm.nih.gov/pubmed/15056470. https://doi.org/10.1016/j.nbd.2003.12.015
  9. Myint AM, Kim YK, Verkerk R, Scharpé S, Steinbusch H, Leonard B. Kynurenine pathway in major depression: evidence of impaired neuroprotection. J Affect Disord. 2007; 98 (1–2): 143-51. https://www.ncbi.nlm.nih.gov/pubmed/16952400. https://doi.org/10.1016/j.jad.2006.07.013
  10. Widner B, Leblhuber F, J, Walli, Tilz GP, Demel U, Fuchs D. Tryptophan degradation and immune activationin Alzheimer’s disease. J Neurol Transm. 2000; 107: 343-353. https://www.ncbi.nlm.nih.gov/pubmed/10821443. https://doi.org/10.1007/s007020050029